Phase I study of vorinostat with gefitinib in BIM deletion polymorphism/epidermal growth factor receptor mutation double‐positive lung cancer

Patients with epidermal growth factor receptor (EGFR)‐mutated non‐small cell lung cancer (NSCLC) harboring BIM deletion polymorphism (BIM deletion) have poor responses to EGFR TKI. Mechanistically, the BIM deletion induces preferential splicing of the non‐functional exon 3‐containing isoform over th...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Cancer Sci
Autors principals: Takeuchi, Shinji, Hase, Tetsunari, Shimizu, Shinobu, Ando, Masahiko, Hata, Akito, Murakami, Haruyasu, Kawakami, Takahiro, Nagase, Katsuhiko, Yoshimura, Kenichi, Fujiwara, Tadami, Tanimoto, Azusa, Nishiyama, Akihiro, Arai, Sachiko, Fukuda, Koji, Katakami, Nobuyuki, Takahashi, Toshiaki, Hasegawa, Yoshinori, Ko, Tun Kiat, Ong, S. Tiong, Yano, Seiji
Format: Artigo
Idioma:Inglês
Publicat: John Wiley and Sons Inc. 2020
Matèries:
Original Articles
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC7004511/
https://ncbi.nlm.nih.gov/pubmed/31782583
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/cas.14260
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars